相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum
J. Lian et al.
CELL DEATH AND DIFFERENTIATION (2011)
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma
F. Morschhauser et al.
ANNALS OF ONCOLOGY (2010)
Effect of FCGR2A and FCGR3A variants on CLL outcome
David Dornan et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
The clinical application of monoclonal antibodies in chronic lymphocytic leukemia
Samantha M. Jaglowski et al.
BLOOD (2010)
Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response
Riad Abes et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling
Simone de Haij et al.
CANCER RESEARCH (2010)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
Anti-CD20 monoclonal antibodies: historical and future perspectives
Sean H. Lim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance
Laura Bonapace et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Investigational Immunotherapeutics for B-Cell Malignancies
Alfonso Quintas-Cardama et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells
R. Shimizu et al.
LEUKEMIA (2010)
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
David M. Goldenberg et al.
BLOOD (2009)
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
Farrukh T. Awan et al.
BLOOD (2009)
Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a vaccinal effect of rituximab
Shannon P. Hilchey et al.
BLOOD (2009)
Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
Junji Hiraga et al.
BLOOD (2009)
Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
Siao-Yi Wang et al.
BLOOD (2009)
Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
Mario I. Vega et al.
CLINICAL CANCER RESEARCH (2009)
Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcγRIIIb and MHC class II expression on the phagocytotic neutrophils
Mami Shibata-Koyama et al.
EXPERIMENTAL HEMATOLOGY (2009)
Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
Ellen J. Schlette et al.
LEUKEMIA & LYMPHOMA (2009)
Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis
Claudia Stolz et al.
BLOOD (2008)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers et al.
BLOOD (2008)
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, and FcγRIV
Veronique Minard-Colin et al.
BLOOD (2008)
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
Anton Hagenbeek et al.
BLOOD (2008)
Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis
Andrey Ivanov et al.
CLINICAL CANCER RESEARCH (2008)
A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma
Emilian Racila et al.
CLINICAL CANCER RESEARCH (2008)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial
Danielle Canioni et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Wyndham H. Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats
Tomonori Tawara et al.
JOURNAL OF IMMUNOLOGY (2008)
Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells
John O. Richards et al.
MOLECULAR CANCER THERAPEUTICS (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Siao-Yi Wang et al.
BLOOD (2008)
Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study
Bertrand Coiffier et al.
BLOOD (2008)
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone
Minna Taskinen et al.
CLINICAL CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Emanuela Carlotti et al.
HAEMATOLOGICA (2007)
FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Zdravko Mitrovic et al.
HAEMATOLOGICA (2007)
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
Holger Schulz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine
Line Groth-Pedersen et al.
CANCER RESEARCH (2007)
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy
Ali R. Jazirehi et al.
CANCER RESEARCH (2007)
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Dong Hwan Kim et al.
BLOOD (2006)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20
Jessica L. Teeling et al.
JOURNAL OF IMMUNOLOGY (2006)
Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study
Jane N. Winter et al.
BLOOD (2006)
Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy
Y Hamaguchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes
PV Beum et al.
JOURNAL OF IMMUNOLOGY (2006)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
W Hiddemann et al.
BLOOD (2005)
Depletion of B cells by a humanized Anti-CD20 antibody PRO70769 in Macaca fascicularis
Y Vugmeyster et al.
JOURNAL OF IMMUNOTHERAPY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-Cell lymphoma, progressive after rituximab
SJ Horning et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
Rituximab inhibits p38 MAPK activity in 2F7 BNHL and decreases IL-10 transcription: Pivotal role of p38 MAPK in drug resistance
MI Vega et al.
ONCOGENE (2004)
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg et al.
BLOOD (2004)
Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia
AD Kennedy et al.
JOURNAL OF IMMUNOLOGY (2004)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling et al.
BLOOD (2004)
Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcγRIIIa functional polymorphism
R Niwa et al.
CLINICAL CANCER RESEARCH (2004)
Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:: 9-year follow-up
MS Czuczman et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
R Forstpointner et al.
BLOOD (2004)
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy
JJ Uchida et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Complement activation determines the therapeutic activity of rituximab in vivo
N Di Gaetano et al.
JOURNAL OF IMMUNOLOGY (2003)
Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)
N Mounier et al.
BLOOD (2003)
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance
R Bannerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma
JD Hainsworth et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism
IM Pedersen et al.
BLOOD (2002)
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
JC Byrd et al.
BLOOD (2002)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Complement activation plays a key role in the side-effects of rituximab treatment
LE van der Kolk et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells
N Selenko et al.
LEUKEMIA (2001)
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
MS Kaminski et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma
WK Weng et al.
BLOOD (2001)
Rituximab using a thrice weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)